Roche starts Swiss cooperation
Zürich – The Swiss biotech company Molecular Partners has begun a cooperation with Roche on its proprietary DRP technology. DRP, or designed repeat proteins, are new non-antibody scaffolds that can be applied to different targets in-vivo and in-vitro. Molecular Partners will select DRPs for targets delivered by Roche and will carry out further analyses and development. Both partners agreed not to disclose the financial terms of their agreement.